Application of circular RNA circSMAD3 in preparation of medicine for preventing and treating myocardial remodeling and heart failure

By studying the expression and function of circular RNA circSMAD3, it was discovered that its inhibitory effect in myocardial remodeling and heart failure was found, providing new drug targets and treatment strategies, and solving the existing technology of central muscle remodeling and heart failure treatment. Inadequately, effective improvement of cardiomyocyte damage has been achieved.

CN119061130AInactive Publication Date: 2024-12-03TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410301035.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-03-15
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing drug therapy is not sufficient to reduce the risk of death caused by heart failure and decompensation, and lacks effective solutions for cardiomyocyte damage. The role of circular RNA circSMAD3 in myocardial remodeling and heart failure Not fully studied.

Method used

By determining the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure, we constructed circSMAD3 overexpressing adenovirus and shRNA adenovirus targeting cyclization sites, and conducted myocardial remodeling and heart failure studies in mouse models, and found that circSMAD3 could be used. Significantly inhibit cardiomyocyte hypertrophy and fibroblast activation, and design and prepare drugs to prevent and treat myocardial remodeling and heart failure.

Benefits of technology

circSMAD3 significantly improves myocardial remodeling and heart failure, providing new drug targets and therapeutic strategies, which can be used as a target gene or small molecule compound agonist in gene therapy to prevent and treat myocardial remodeling and heart failure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061130A_ABST
    Figure CN119061130A_ABST
Patent Text Reader

Abstract

The invention provides application of circular RNA circSMAD3 in preparation of medicine for preventing and treating myocardial remodeling and heart failure, and belongs to the field of biological medicine, the circular RNA circSMAD3 is non-coding RNA, and the nucleotide sequence is shown as SEQ ID NO.1. The circular RNA circSMAD3 is used for overexpressing adenovirus and knocking down adenovirus based on short hairpin structure to infect primary myocardial cells and cardiac fibroblasts of mice, and the circular RNA circSMAD3 can be used for preventing and treating myocardial remodeling and heart failure. The result shows that circSMAD3 significantly inhibits cardiac hypertrophy and activation of cardiac fibroblasts. When the function of circSMAD3 is explored in vivo, circSMAD3 is overexpressed in a mouse myocardial remodeling and heart failure model induced by transverse aortic constriction (TAC) and myocardial infarction (MI) by using a caudal vein injection mode by using a 9-type adeno-associated virus (AAV9) overexpressed by circSMAD3 myocardial specificity. The result shows that the circSMAD3 overexpression can effectively relieve myocardial hypertrophy and myocardial fibrosis caused by TAC and MI, and obviously improve the cardiac function of mice. The invention provides a new medicine for preventing and treating myocardial remodeling and heart failure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the use of circular RNA circSMAD3 in the preparation of drugs for preventing and treating myocardial remodeling and heart failure. Background Art

[0002] Heart failure is the main cardiovascular disease that threatens the life and health of Chinese people, and it causes a huge social medical burden. With the continuous aging of my country's population and the continuous changes in the social demographic structure, the consequences of cardiovascular diseases such as heart failure are becoming more and more serious. When the heart cannot provide sufficient perfusion to the tissue to meet its needs, heart failure often occurs, leading to fatigue, dyspnea, multiple organ dysfunction and premature death. In response to external stimuli, the heart undergoes pathological cardiac remodeling, including myocardial hypertrophy, interstitial fibrosis and activation of inflammatory pathways. Although there are currently a variety of drugs that can effectively treat it, there is still a residual risk of heart damage and decompensation leading to patient death. However, current drug therapies mainly target neurohormonal signaling pathways, such as renin-angiotensin system inhibitors and beta-blockers. But these measures are not enough to reduce this risk. In addition, there is no drug to solve the residual risk of heart failure from the perspective of repairing myocardial cell damage. Therefore, based on clinical needs, finding a new treatment for myocardial remodeling and heart failure is of great practical significance for patients with heart failure.

[0003] The transforming growth factor β (TGFβ) signaling pathway is the most critical pathway for regulating cardiac remodeling and heart failure. Currently, many researchers have tried to focus on TGFβ1 to develop key targets (including antibodies or inhibitors) for the treatment of myocardial remodeling or heart failure, and have conducted a lot of research on it. However, due to the wide range of functions of TGFβ1 and the relatively large number of side effects it causes, these newly developed drugs cannot pass the evaluation of later clinical trials. Therefore, the progress in the development of drugs for the treatment of myocardial remodeling targeting TGFβ1 is still difficult.

[0004] Circular RNA (circRNAs) is a new type of non-coding RNA and epigenetic regulator with a covalently closed circular structure without a 5' cap and a 3' tail, which is derived from the reverse splicing process of the precursor RNA. With the continuous development of high-throughput sequencing technology, more and more circular RNA molecules have been discovered and their functions have been clarified. At present, many studies have shown that circRNA has the functions of acting as a miRNA sponge, binding to proteins, regulating genetic transcription and translating proteins. In addition, due to its special covalently closed structure, circRNA has stronger resistance to digestion and stability than linear RNA in response to external stimuli. Therefore, it has gradually become a reliable diagnostic indicator and potential therapeutic target for various cardiovascular diseases including myocardial remodeling, and has received great attention from researchers. Therefore, it is of great practical significance to continuously explore circRNAs that play a key regulatory role in the pathophysiology of different diseases and deeply analyze their functions, which will provide new intervention strategies for the treatment of pathological myocardial remodeling and develop new drugs. Although more and more studies have found that circRNAs can serve as biomarkers and potential therapeutic targets for cardiovascular diseases, the role of the most critical circRNAs in regulating myocardial remodeling and heart failure in the treatment and diagnosis of myocardial remodeling and heart failure has not been thoroughly studied and further research is needed. Summary of the invention

[0005] In order to solve the above problems, the purpose of the present invention is to provide the use of circSMAD3 in the preparation of drugs for preventing and treating myocardial remodeling and heart failure. The purpose of the present invention is to clarify the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure, and to clarify that circSMAD3 can be used as a new drug or drug target to prepare drugs for preventing and treating myocardial remodeling and heart failure.

[0006] The embodiment of the present invention provides the use of circular RNA circSMAD3 in preparing a drug for preventing and treating myocardial remodeling and heart failure. The circular RNA circSMAD3 is a non-coding RNA, and the nucleotide sequence is shown in SEQ ID NO.1.

[0007] The present invention first determined the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure, as follows: 6 mice with myocardial remodeling and heart failure models induced by transverse aortic constriction and myocardial infarction were randomly selected, and quantitative primers for specific detection of circular RNA circSMAD3 cyclization sites were designed. The results showed that the expression of circular RNA circSMAD3 in the heart tissue of two myocardial remodeling mouse models was significantly downregulated. Furthermore, the heart tissue of mice 8 weeks after TAC surgery was separated by a perfusion system, and primary cardiomyocytes and fibroblasts of adult mice were successfully extracted, and the expression of circSMAD3 was detected by qRT-PCR technology. The expression of circSMAD3 was downregulated in the cardiomyocytes and fibroblasts isolated from the TAC group. Similarly, angiotensin II (AngII) was used to stimulate primary cardiomyocytes of neonatal mice and TGFβ1 was used to stimulate primary cardiac fibroblasts of mice to construct an in vitro model of myocardial remodeling, and the results showed that the expression of circSMAD3 was significantly downregulated. These results show that the expression of circSMAD is negatively correlated with myocardial remodeling and heart failure.

[0008] Secondly, the present invention studies the regulatory effect of circular RNA circSMAD3 on myocardial remodeling in an in vitro cell model. The specific operations are as follows: The present invention successfully constructed a circSMAD3 overexpression adenovirus and a knockdown adenovirus based on a short hairpin structure of shRNA targeting the cyclization site. After infecting primary cardiomyocytes and cardiac fibroblasts of suckling mice for 24 hours, AngII was used to stimulate cardiomyocytes and TGFβ1 was used to stimulate fibroblasts. The results showed that circSMAD3 overexpression significantly inhibited myocardial hypertrophy induced by angiotensin II and activation of cardiac fibroblasts induced by TGFβ1 (enhanced proliferation and migration ability). The above results show that circSMAD3 can significantly inhibit myocardial hypertrophy and activation of fibroblasts.

[0009] In addition, the present invention also studies the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure in an in vivo animal model, as follows: mouse myocardial remodeling and heart failure models were constructed by TAC and myocardial infarction, and adeno-associated virus type 9 with myocardial-specific overexpression of circular RNA circSMAD3 was used to infect the heart tissues of the above two mouse models and successfully overexpress circSMAD3. The results showed that circSMAD3 overexpression can significantly inhibit myocardial hypertrophy and myocardial fibrosis, and effectively improve the abnormal cardiac function of mice caused by TAC and MI.

[0010] From the above results, it can be seen that circular RNA circSMAD3 has the effect of preventing and treating myocardial remodeling and heart failure, and can be used as a target gene in gene therapy to design and prepare drugs and / or biological reagents for preventing and treating myocardial remodeling and heart failure, and achieve the purpose of preventing and treating myocardial remodeling and heart failure through genetic engineering technology. For example, taking circular RNA circSMAD3 as the target gene, designing a promoter that can increase the expression of circSMAD3, synthesizing it by chemical methods, injecting it into the human body to overexpress circSMAD3 through gene editing to treat myocardial remodeling and heart failure; in addition, small molecule compound agonists can be designed with circSMAD3 as the target, and molecules that can specifically overexpress circSMAD3 can be found through screening, thereby providing new therapeutic molecules for the treatment of myocardial remodeling and heart failure.

[0011] In view of the above functions of circular RNA circSMAD3, the present invention provides the use of circular RNA circSMAD3 as a drug target in the preparation of drugs for preventing and treating myocardial remodeling and heart failure.

[0012] The preferred technical solution of the present invention is that the myocardial remodeling and heart failure are directly used as drugs for preventing and treating myocardial remodeling and heart failure.

[0013] A preferred technical solution of the present invention: the pharmacologically active ingredients of the drug include: substances that regulate the expression of circSMAD3; the substances that regulate the expression of circSMAD3 are selected from: recombinant expression vectors that upregulate the expression or overexpress circSMAD3, recombinant viral vectors that upregulate the expression or overexpress circSMAD3, or other promoters that can upregulate the expression or overexpress circSMAD3.

[0014] Compared with the prior art, the present invention has the following advantages and effects:

[0015] (1) The present invention found that circSMAD3 has the effect of improving myocardial remodeling and heart failure.

[0016] (2) Based on the function of circSMAD3 in improving myocardial remodeling and heart failure, it provides a target for the development of drugs to prevent and treat myocardial remodeling and heart failure. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 The expression changes of circSMAD3 in myocardial remodeling models in vivo and in vitro;

[0019] Figure 1 A is the echocardiogram of mice after the TAC-induced myocardial remodeling model was successfully established;

[0020] Figure 1 B is real-time fluorescence quantitative PCR (qRT-PCR) to evaluate the expression changes of CircSMAD3 in the heart tissue of mice with TAC-induced myocardial remodeling;

[0021] Figure 1 C is real-time fluorescence quantitative PCR (qRT-PCR) to evaluate the perfusion isolation of cardiomyocytes and fibroblasts in mice with TAC-induced myocardial remodeling, and to detect the expression changes of circSMAD3; Figure 1 D is the echocardiogram of mice after the MI-induced myocardial remodeling model was successfully established;

[0022] Figure 1 E is qRT-PCR evaluation of the expression changes of CircSMAD3 in the heart tissue of mice with MI-induced myocardial remodeling; Figure 1 F is the expression difference result of CircSMAD3 in the angiotensin II (AngII)-induced cardiomyocyte hypertrophy model;

[0023] Figure 1 G is the expression difference result of CircSMAD3 in TGFβ1-induced cardiac fibroblast model;

[0024] Figure 1 HI is the expression difference of CircSMAD3 in cardiomyocytes (CM) and cardiac fibroblasts (CF) evaluated by qRT-PCR;

[0025] Figure 2 circSMAD3 inhibits angiotensin 2-induced cardiac hypertrophy;

[0026] Figure 2 A is the expression changes of circSMAD3 and cardiac hypertrophy genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after overexpression of circSMAD3 in primary mouse cardiomyocytes;

[0027] Figure 2 B is the expression changes of circSMAD3 and cardiac hypertrophy genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after knocking out circSMAD3 in primary mouse cardiomyocytes;

[0028] Figure 2C is the area of ​​cardiomyocytes detected by phalloidin assay after overexpression of circSMAD3 and stimulation of angiotensin 2 in primary mouse cardiomyocytes;

[0029] Figure 2 D is the quantitative analysis of the area size of myocardial cells;

[0030] Figure 2 E is the area of ​​cardiomyocytes detected by phalloidin assay after knocking out circSMAD3 and stimulating angiotensin 2 in primary cardiomyocytes of mice;

[0031] Figure 2 F is the quantitative analysis of the cardiomyocyte area.

[0032] Figure 3 circSMAD3 inhibits transforming growth factor β (TGFβ)-induced cardiac fibroblast activation;

[0033] Figure 3 A is the expression changes of circSMAD3 and fibrosis marker genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after overexpression of circSMAD3 in mouse primary cardiac fibroblasts;

[0034] Figure 3 B is the expression changes of circSMAD3 and fibrosis marker genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after knocking out circSMAD3 in mouse primary cardiac fibroblasts;

[0035] Figure 3 C is the CCK8 assay to detect the growth activity of cardiac fibroblasts after overexpression of circSMAD3 and stimulation with transforming growth factor-β in mouse primary cardiac fibroblasts;

[0036] Figure 3 D is the CCK8 assay to detect the growth activity of cardiac fibroblasts after circSMAD3 knockout in primary mouse cardiac fibroblasts;

[0037] Figure 3 E: After overexpression of circSMAD3 in mouse primary cardiac fibroblasts and stimulation with transforming growth factor-β, the migration ability of cardiac fibroblasts was detected by scratch assay;

[0038] Figure 3 F is the scratch assay to detect the migration ability of cardiac fibroblasts after circSMAD3 knockout in primary mouse cardiac fibroblasts;

[0039] Figure 3 GH is the statistical analysis of fibroblast migration ability after overexpression or knockout of circSMAD3;

[0040] Figure 3 IL is the difference in fibroblast proliferation ability and its statistical difference analysis after overexpression or knockout of circSMAD3 by EDU experiment.

[0041] Figure 4 Effect of cardiac-specific overexpression of circSMAD3 on TAC-induced pathological myocardial remodeling;

[0042] Figure 4 A is qRT-PCR evaluation of circSMAD3 overexpression efficiency;

[0043] Figure 4 B is the echocardiogram of mice infected with adeno-associated virus overexpressing circSMAD3 and undergoing TAC.

[0044] Figure 4 C shows the changes of ejection fraction (EF) in each group of mice;

[0045] Figure 4 D is the change of short axis shrinkage rate (FS) of mice in each group;

[0046] Figure 4 E is the appearance of the heart size of mice in each group. HE staining and WGA staining show the area of ​​myocardial cells; Sirius red staining (Siurus Red) shows the changes in the degree of cardiac fibrosis in mice;

[0047] Figure 4 F is the change of heart / tibia length ratio in each group of mice;

[0048] Figure 4 G is the quantitative diagram of the area size of myocardial cells in each group of mice;

[0049] Figure 4 H is the quantitative diagram of the degree of cardiac fibrosis in each group of mice;

[0050] Figure 4 I is qRT-PCR detection of the expression changes of cardiac tissue hypertrophy marker genes (Nppa, Nppb and Myh7) and fibrosis marker genes (Collagen I and Collagen III) in each group of mice.

[0051] Figure 5 Effects of cardiac-specific overexpression of circSMAD3 on pathological myocardial remodeling induced by MI;

[0052] Figure 5 A is qRT-PCR evaluation of CircSMAD3 overexpression efficiency;

[0053] Figure 5BG: qRT-PCR detection of the expression changes of hypertrophy marker genes (Nppa, Nppb and Myh7) and fibrosis marker genes (Collagen I, Collagen III and ACTA2) in cardiac tissue of each group of mice;

[0054] Figure 5 H. Changes in heart / tibia length ratio of mice in each group;

[0055] Figure 5 I shows the echocardiographic changes of mice in each group after infection with adeno-associated virus overexpressing circSMAD3 and MI surgery;

[0056] Figure 5 J is the changes of ejection fraction (EF) and short axis contraction fraction (FS) in each group of mice;

[0057] Figure 5 K is Masson staining to detect changes in cardiac fibrosis after myocardial infarction;

[0058] Figure 5 L is the quantitative graph of the degree of cardiac fibrosis in each group of mice. DETAILED DESCRIPTION

[0059] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0060] Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the invention claimed for protection, but merely represents selected embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0061] It should be noted that similar reference numerals and letters denote similar items in the following drawings, and therefore, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.

[0062] In the description of the present invention, it should be understood that the terms "center", "longitudinal", "lateral", "length", "width", "thickness", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside", "clockwise", "counterclockwise" and the like indicate orientations or positional relationships based on the orientations or positional relationships shown in the accompanying drawings, and are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the referred device or element must have a specific orientation, be constructed and operated in a specific orientation, and therefore should not be understood as a limitation on the present invention.

[0063] In addition, the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "plurality" is two or more, unless otherwise clearly and specifically defined.

[0064] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be directly connected or indirectly connected through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0065] In the present invention, unless otherwise clearly specified and limited, a first feature being "above" or "below" a second feature may include that the first and second features are in direct contact, or may include that the first and second features are not in direct contact but are in contact through another feature between them. Moreover, a first feature being "above", "above" and "above" a second feature includes that the first feature is directly above and obliquely above the second feature, or simply indicates that the first feature is higher in level than the second feature. A first feature being "below", "below" and "below" a second feature includes that the first feature is directly below and obliquely below the second feature, or simply indicates that the first feature is lower in level than the second feature.

[0066] See also Figure 1-5, Application of circular RNA circSMAD3 in the preparation of drugs for preventing and treating myocardial remodeling and heart failure, in order to solve the above problems, the purpose of the present invention is to provide the application of circSMAD3 in the preparation of drugs for preventing and treating myocardial remodeling and heart failure. The purpose of the present invention is to clarify the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure, and to clarify that circSMAD3, as a new drug or drug target, can be used to prepare drugs for preventing and treating myocardial remodeling and heart failure.

[0067] In the present invention, the technical solution adopted is as follows:

[0068] The circular RNA circSMAD3 is a non-coding RNA, and the nucleotide sequence is shown in SEQ ID NO.1.

[0069] The present invention first determined the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure, as follows: 6 mice with myocardial remodeling and heart failure models induced by transverse aortic constriction and myocardial infarction were randomly selected, and quantitative primers for specific detection of circular RNA circSMAD3 cyclization sites were designed. The results showed that the expression of circular RNA circSMAD3 in the heart tissue of two myocardial remodeling mouse models was significantly downregulated. Furthermore, the heart tissue of mice 8 weeks after TAC surgery was separated by a perfusion system, and primary cardiomyocytes and fibroblasts of adult mice were successfully extracted, and the expression of circSMAD3 was detected by qRT-PCR technology. The expression of circSMAD3 was downregulated in the cardiomyocytes and fibroblasts isolated from the TAC group. Similarly, angiotensin II (AngII) was used to stimulate primary cardiomyocytes of neonatal mice and TGFβ1 was used to stimulate primary cardiac fibroblasts of mice to construct an in vitro model of myocardial remodeling, and the results showed that the expression of circSMAD3 was significantly downregulated. These results show that the expression of circSMAD is negatively correlated with myocardial remodeling and heart failure.

[0070] Secondly, the present invention studies the regulatory effect of circular RNA circSMAD3 on myocardial remodeling in an in vitro cell model. The specific operations are as follows: The present invention successfully constructed a circSMAD3 overexpression adenovirus and a knockdown adenovirus based on a short hairpin structure of shRNA targeting the cyclization site. After infecting primary cardiomyocytes and cardiac fibroblasts of suckling mice for 24 hours, AngII was used to stimulate cardiomyocytes and TGFβ1 was used to stimulate fibroblasts. The results showed that circSMAD3 overexpression significantly inhibited myocardial hypertrophy induced by angiotensin II and activation of cardiac fibroblasts induced by TGFβ1 (enhanced proliferation and migration ability). The above results show that circSMAD3 can significantly inhibit myocardial hypertrophy and activation of fibroblasts.

[0071] In addition, the present invention also studies the relationship between circular RNA circSMAD3 and myocardial remodeling and heart failure in an in vivo animal model, as follows: mouse myocardial remodeling and heart failure models were constructed by TAC and myocardial infarction, and adeno-associated virus type 9 with myocardial-specific overexpression of circular RNA circSMAD3 was used to infect the heart tissues of the above two mouse models and successfully overexpress circSMAD3. The results showed that circSMAD3 overexpression can significantly inhibit myocardial hypertrophy and myocardial fibrosis, and effectively improve the abnormal cardiac function of mice caused by TAC and MI.

[0072] From the above results, it can be seen that circular RNA circSMAD3 has the effect of preventing and treating myocardial remodeling and heart failure, and can be used as a target gene in gene therapy to design and prepare drugs and / or biological reagents for preventing and treating myocardial remodeling and heart failure, and achieve the purpose of preventing and treating myocardial remodeling and heart failure through genetic engineering technology. For example, taking circular RNA circSMAD3 as the target gene, designing a promoter that can increase the expression of circSMAD3, synthesizing it by chemical methods, injecting it into the human body to overexpress circSMAD3 through gene editing to treat myocardial remodeling and heart failure; in addition, small molecule compound agonists can be designed with circSMAD3 as the target, and molecules that can specifically overexpress circSMAD3 can be found through screening, thereby providing new therapeutic molecules for the treatment of myocardial remodeling and heart failure.

[0073] In view of the above functions of circular RNA circSMAD3, the present invention provides the use of circular RNA circSMAD3 as a drug target in the preparation of drugs for preventing and treating myocardial remodeling and heart failure.

[0074] The preferred technical solution of the present invention is that the myocardial remodeling and heart failure are directly used as drugs for preventing and treating myocardial remodeling and heart failure.

[0075] A preferred technical solution of the present invention: the pharmacologically active ingredients of the drug include: substances that regulate the expression of circSMAD3; the substances that regulate the expression of circSMAD3 are selected from: recombinant expression vectors that upregulate the expression or overexpress circSMAD3, recombinant viral vectors that upregulate the expression or overexpress circSMAD3, or other promoters that can upregulate the expression or overexpress circSMAD3.

[0076] Compared with the prior art, the present invention has the following advantages and effects:

[0077] (1) The present invention found that circSMAD3 has the effect of improving myocardial remodeling and heart failure.

[0078] (2) Based on the function of circSMAD3 in improving myocardial remodeling and heart failure, it provides a target for the development of drugs to prevent and treat myocardial remodeling and heart failure. (IV) Description of the drawings

[0080] Figure 1 The expression changes of circSMAD3 in myocardial remodeling models in vivo and in vitro; Figure 1 A is the echocardiogram of mice after the TAC-induced myocardial remodeling model was successfully established; Figure 1 B is real-time fluorescence quantitative PCR (qRT-PCR) to evaluate the expression changes of CircSMAD3 in the heart tissue of mice with TAC-induced myocardial remodeling; Figure 1 C is real-time fluorescence quantitative PCR (qRT-PCR) to evaluate the perfusion isolation of cardiomyocytes and fibroblasts in mice with TAC-induced myocardial remodeling, and to detect the expression changes of circSMAD3; Figure 1 D is the echocardiogram of mice after the MI-induced myocardial remodeling model was successfully established; Figure 1 E is qRT-PCR evaluation of the expression changes of CircSMAD3 in the heart tissue of mice with MI-induced myocardial remodeling; Figure 1 F is the expression difference result of CircSMAD3 in the angiotensin II (AngII)-induced cardiomyocyte hypertrophy model; Figure 1 G is the expression difference result of CircSMAD3 in TGFβ1-induced cardiac fibroblast model; Figure 1 HI is qRT-PCR evaluation of the expression difference of CircSMAD3 in cardiomyocytes (CM) and cardiac fibroblasts (CF).

[0081] Figure 2 circSMAD3 inhibits angiotensin 2-induced cardiac hypertrophy; Figure 2 A is the expression changes of circSMAD3 and cardiac hypertrophy genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after overexpression of circSMAD3 in primary mouse cardiomyocytes; Figure 2 B is the expression changes of circSMAD3 and cardiac hypertrophy genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after knocking out circSMAD3 in primary mouse cardiomyocytes; Figure 2 C is the area of ​​cardiomyocytes detected by phalloidin assay after overexpression of circSMAD3 and stimulation of angiotensin 2 in primary cardiomyocytes of mice; Figure 2 D is the quantitative analysis of the area size of myocardial cells; Figure 2 E is the area of ​​cardiomyocytes detected by phalloidin assay after knocking out circSMAD3 and stimulating angiotensin 2 in primary cardiomyocytes of mice; Figure 2F is the quantitative analysis of the cardiomyocyte area.

[0082] Figure 3 circSMAD3 inhibits transforming growth factor β (TGFβ)-induced cardiac fibroblast activation; Figure 3 A is the expression changes of circSMAD3 and fibrosis marker genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after overexpression of circSMAD3 in mouse primary cardiac fibroblasts; Figure 3 B is the expression changes of circSMAD3 and fibrosis marker genes evaluated by real-time fluorescence quantitative PCR (qRT-PCR) after knocking out circSMAD3 in mouse primary cardiac fibroblasts; Figure 3 C is the CCK8 assay to detect the growth activity of cardiac fibroblasts after overexpression of circSMAD3 and stimulation with transforming growth factor-β in mouse primary cardiac fibroblasts; Figure 3 D is the CCK8 assay to detect the growth activity of cardiac fibroblasts after circSMAD3 knockout in primary mouse cardiac fibroblasts; Figure 3 E: After overexpression of circSMAD3 in mouse primary cardiac fibroblasts and stimulation with transforming growth factor-β, the migration ability of cardiac fibroblasts was detected by scratch assay; Figure 3 F is the scratch assay to detect the migration ability of cardiac fibroblasts after circSMAD3 knockout in primary mouse cardiac fibroblasts; Figure 3 GH is the statistical analysis of fibroblast migration ability after overexpression or knockout of circSMAD3; Figure 3 IL is the difference in fibroblast proliferation ability and its statistical difference analysis after overexpression or knockout of circSMAD3 by EDU experiment.

[0083] Figure 4 Effect of cardiac-specific overexpression of circSMAD3 on TAC-induced pathological myocardial remodeling; Figure 4 A is qRT-PCR evaluation of circSMAD3 overexpression efficiency; Figure 4 B is the echocardiogram of mice infected with adeno-associated virus overexpressing circSMAD3 and undergoing TAC. Figure 4 C shows the changes of ejection fraction (EF) in each group of mice; Figure 4 D is the change of short axis shrinkage rate (FS) of mice in each group; Figure 4 E is the appearance of the heart size of mice in each group. HE staining and WGA staining show the area of ​​myocardial cells; Sirius red staining (Siurus Red) shows the changes in the degree of cardiac fibrosis in mice. Figure 4 F is the change of heart / tibia length ratio in each group of mice; Figure 4G is the quantitative diagram of the area size of myocardial cells in each group of mice; Figure 4 H is the quantitative diagram of the degree of cardiac fibrosis in each group of mice; Figure 4 I is qRT-PCR detection of the expression changes of cardiac tissue hypertrophy marker genes (Nppa, Nppb and Myh7) and fibrosis marker genes (Collagen I and Collagen III) in each group of mice.

[0084] Figure 5 Effects of cardiac-specific overexpression of circSMAD3 on pathological myocardial remodeling induced by MI; Figure 5 A is qRT-PCR evaluation of CircSMAD3 overexpression efficiency; Figure 5 BG: qRT-PCR detection of the expression changes of hypertrophy marker genes (Nppa, Nppb and Myh7) and fibrosis marker genes (Collagen I, Collagen III and ACTA2) in cardiac tissue of each group of mice; Figure 5 H. Changes in heart / tibia length ratio of mice in each group; Figure 5 I shows the echocardiographic changes of mice in each group after infection with adeno-associated virus overexpressing circSMAD3 and MI surgery; Figure 5 J is the changes of ejection fraction (EF) and short axis contraction fraction (FS) in each group of mice; Figure 5 K is Masson staining to detect changes in cardiac fibrosis after myocardial infarction; Figure 5 L is the quantitative graph of the degree of cardiac fibrosis in each group of mice. (V) Specific implementation methods

[0086] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.

[0087] In the following examples, the reagents described are all commercially available unless otherwise specified, and the technical means and methods described are all conventional technical means and methods in the art unless otherwise specified.

[0088] The human and mouse circSMAD3 sequences in the following examples are shown in SEQ ID NO.1:

[0089] Human h-circSMAD3 sequence:

[0090] GTCCCTGGATGGCCGGTTGCAGGTGTCCCATCGGAAGGGGCTCCCTCATGTCATCTACTGCCGCCTGTGGCGATGGCCAGACCTGCACAGCCACCACGAGCTACGGGCCATGGAGCTGTGTGAGTTCGCCTTCAATATGAAGAAGGACGAGGTCTGCGTGAATCCCTACCACTACCAGAGAGTAGAGACACCAGTTCTACCTCCTGTGTTGGTGCCACGCCACACAGAGATCCCGGCCGAGTTCCCCCCACTGGACGACTACAGCCATTCCATCCCCGAAAACACTAACTTCCCCGCAGGCATCGAGCCCCAGAGCAATATTCCAGAGACCCCACCCCCTGGCTACCTGAGTGAAGATGGAGAAACCAGTGACCACCAGATGAACCACAGCATGGACGCAGGTTCTCCAAACCTATCCCCGAATCCGATGTCCCCAGCACATAATAACTTGG

[0091] Mouse-derived m-circSMAD3 sequence:

[0092] GTCACTGGATGGTCGGCTGCAGGTGTCCCATCGGAAGGGGCTCCCTCACGTTATCTACTGCCGCCTGTGGCGATGGCCCGACCTGCACAGCCACCATGAATTACGGGCCATGGAGCTCTGTGAGTTTGCCTTCAACATGAAGAAGGATGAAGTGTGTGTAAATCCTTACCACTATCAGAGAGTAGAGACGCCAGTTCTACCTCCAGTGTTGGTGCCACGCCACACCGAGATCCCGGCCGAGTTCCCCCCACTGGATGACTACAGCCATTCCATTCCCGAGAACACTAACTTCCCTGCTGGCATTGAGCCCCAGAGCAATATTCCAGAAACCCCACCTCCTGGCTACCTGAGTGAAGATGGAGAAACCAGTGACCACCAGATGAACCACAGCATGGACGCAGGTTCTCCAAACCTCTCCCCGAATCCGATGTCCCCAGCACACAATAACTTGG

[0093] Example 1

[0094] This example provides an experimental method for using circSMAD3 (nucleotide sequence as shown in SEQ ID NO. 11) as a marker for diagnosing pathological myocardial remodeling.

[0095] (1) Transverse aortic constriction (TAC) to construct a myocardial remodeling model

[0096] Male C57BL / 6 mice weighing about 25 g were randomly divided into a sham operation group (Sham) and a myocardial remodeling model group (TAC). The mice were weighed and anesthetized by intraperitoneal injection (anesthetic dose: 1% pentobarbital 5ul / g). After depilatory cream was used to remove the chest hair, the mice were fixed in a supine position on a mouse fixation table, and the skin was disinfected with iodine. After blunt separation of the tissues around the trachea to expose the trachea, a midline incision was made in the chest, the sternum was cut (not exceeding the sternal angle), the thymus was bluntly separated, and the aortic arch was found; a small curved retractor was used to pass through the bottom of the aortic arch to separate the connective tissue and pass the circle at the top of the retractor with 7-0 non-traumatic sterile silk thread, the retractor was pulled back and the silk thread was brought back to pass through the aortic arch. After placing a pad needle in the aortic arch, it was ligated with silk thread and the pad needle was removed. It can be observed that the pulsation of the right common carotid artery was significantly enhanced, and the model was initially judged to be successfully constructed. Finally, the chest cavity and chest skin were sutured layer by layer and disinfected, and the mice were placed on an electric blanket to keep warm and wait for the mice to recover. After the operation, the mice in the model group and the control group were raised under the same conditions for about 8 weeks, and the successful establishment of the myocardial remodeling model was verified by ultrasonic detection of aortic arch blood flow velocity and cardiac function.

[0097] (2) Myocardial infarction (MI) to establish myocardial remodeling model

[0098] Male C57BL / 6 mice weighing about 25g were randomly divided into a sham operation group (Sham) and a myocardial remodeling model group (MI). The mice were weighed and anesthetized by intraperitoneal injection (anesthetic dose: 1% pentobarbital 5ul / g). After the mice were anesthetized, endotracheal intubation was performed, and the left chest was exposed. The skin was cut and the muscles were bluntly separated. The 3rd or 4th ribs beside the sternum were cut to expose the chest cavity. The pericardium was peeled off to fully expose the heart. The lower edge of the left atrial appendage was used as a mark. The pink left anterior descending branch vessel was visible at about 0.1-0.2cm parallel to the lower edge of the left atrial appendage. It was ligated with 8-0 silk thread here. Tens of seconds after ligation, the left anterior ventricular wall became pale locally. The chest cavity was then closed layer by layer and the mice were placed on an electric blanket to keep warm and wait for the mice to recover. After the operation, the mice in the model group and the control group were raised under the same conditions for about 4 weeks, and the establishment of the myocardial remodeling model was verified by ultrasound detection of cardiac function.

[0099] (3) Isolation of primary cardiomyocytes and cardiac fibroblasts from adult mice using a perfusion system

[0100] First, you need to prepare 500ml of benchtop solution according to the following formula: NaCl4.003g; KCl0.201g; MgCl20.057g; HEPEs1.191g; D-Glucose0.900g; NaH2PO4.2H2O0.187g; Taurine0.625g; BDM0.5g. After preparation, adjust the solution pH to about 7.4. Prepare 1mg / ml type II collagenase and oxygenate. After anesthetizing the mouse, take the mouse heart and place it in ice-cold benchtop solution. Find the aorta and tie it to the bottom of the cannula, and use a syringe to slowly push the benchtop solution to pump out blood. Then place it on the perfusion system and perfuse the digestive enzyme for 25min. After the heart tissue is fully digested, use 1% BSA to stop the digestion. Cut the left ventricle into 1% BSA, bluntly separate and blow to accelerate the separation, filter with a 100-mesh filter, and aspirate the cell suspension into a centrifuge tube. Centrifuge at 500 rpm for 30 seconds, and the precipitate is the primary cardiomyocytes of adult rats. The supernatant is the cardiac fibroblasts, which are collected by centrifugation at 3000 g for 5 minutes.

[0101] (4) Isolation of primary neonatal mouse cardiomyocytes and cardiac fibroblasts

[0102] In this experiment, the instruments needed for the experiment were placed in a clean bench for ultraviolet irradiation overnight. The heart tissues of the suckling mice within 0-3 days after birth were cut and placed in pre-cooled calcium-magnesium-free Hanks solution. After washing away the residual blood, the suckling mouse heart tissues were cut into 2-3mm pieces with sterile microscissors. Then, 7ml2% type II collagenase was used for digestion, 7min each time, and the digestion solution was collected in a 50ml centrifuge tube. After digestion, the collected cell suspension was filtered through a 100-mesh filter to remove larger heart tissue fragments, and then the cells were collected at 1000g, 4℃, and 8min. The cells were resuspended in DMEM with 10% serum added with double antibodies and placed in a T75 culture flask for 2 hours. After 2 hours, the supernatant was the primary cardiomyocytes of the suckling mice, and the adherent cells were cardiac fibroblasts. They can be identified by their respective cell markers.

[0103] (5) Small Animal Cardiac Ultrasound Testing

[0104] Take the surgically treated mice and remove the chest hair with depilatory cream in advance. Use isoflurane for gas anesthesia, fix them in the supine position on the fixed table, apply coupling agent on the chest, and place the ultrasound probe on the chest above the heart of the animal. Use the sensor of the high-resolution imaging system to obtain the two-dimensional cardiac ultrasound image of the small animal, adjust the direction of the probe to obtain the corresponding M-type detection curve, and measure it. Doppler ultrasound is used to detect the blood flow velocity of the mouse aortic arch. The ejection fraction (LVEF) and left ventricular shortening fraction (LVFS) are calculated based on the ultrasound image on the cardiac ultrasound instrument.

[0105] (6) Real-time quantitative PCR (qRT-PCR)

[0106] 1) Extract RNA from cells or tissues. This part extracts RNA from cells according to the instructions of the Trizol kit. The operation is as follows: discard the original culture medium and wash with pre-cooled PBS three times, then add 1ml RNA extraction reagent Trizol and place it on a shaker at 4℃ for 20min. Then use an enzyme-free pipette to collect it and place it in a 1.5ml enzyme-free EP tube; for frozen heart tissue, take out the tissue block from the -80℃ refrigerator, weigh 20mg of the tissue block, place it in a 1.5ml enzyme-free EP tube, add 1ml Trizol and place it in a grinder for grinding. The subsequent steps are exactly the same for cells and tissues: add 200μL chloroform to the EP tube, shake and let it stand for 15min, and then centrifuge at 12000g and 4℃ for 15min. After centrifugation, the liquid in the tube is divided into three phases: the top aqueous phase (RNA phase), the middle milky white skirt-like protein phase, and the bottom DNA phase. Carefully aspirate about 600μL of the top supernatant and transfer it to a new 1.5mL EP tube. Add an equal volume (600 μL) of isopropanol, shake and let stand for 10 minutes, then centrifuge at 12000g and 4°C for 10 minutes. Discard the supernatant and add 1 ml of 75% DEPC ethanol to wash the RNA. Centrifuge at 7500g and 4°C for 5 minutes. Discard the supernatant, invert the EP tube on a clean filter paper, and air-dry at room temperature. Dissolve the RNA with an appropriate amount of enzyme-free water, and measure the RNA concentration and purity using a Nanodrop spectrophotometer.

[0107] 2) Preparation of cDNA. Take 1ug of total RNA and reverse transcribe it into corresponding cDNA according to the instructions of the reverse transcription kit. GAPDH is used as an internal reference for relative standardization. Place the sample in a PCR instrument and perform reverse transcription according to the following reaction program. The reaction temperature program is 37℃15min, 85℃5s, 4℃5min. The amplified cDNA is frozen in a -20℃ refrigerator for use.

[0108] 3) Real-time fluorescence quantitative PCR (qRT-PCR). This experiment used the SYBR dye method for fluorescence quantitative PCR experiments. According to the instructions of the kit, the specific reaction system was as follows: 95℃10min, 95℃5sec, 60℃30sec, 40 cycles, melting curve: 95℃30sec, 60℃1min, 95℃30sec, 60℃1min. The relative amount of the target gene was calculated by the cycle value (Ct value) method 2-ΔΔCT. ΔΔCt = (Ct target gene-Ct housekeeping gene) experimental group-(Ct target gene-Ct housekeeping gene) control group. The specific primer sequences used in the experiment are as follows: h-circSMAD3 upstream primer is 5'-CAGCACATAATAACTTGGGTCCCT-3', and h-circSMAD3 downstream primer is 5'-AACTCACACAGCTCCATGGC-3'. The upstream primer of m-circSMAD3 was 5'-CAGCACACAATAACTTGGGTCACT-3', and the downstream primer of m-circSMAD3 was 5'-AACTCACAGAGCTCCATGGC-3'. The upstream primer of m-ANP was 5'-AGGCAGTCGATTCTGCTTGA-3', and the downstream primer of m-ANP was 5'-CGTGATAGATGAAGGCAGGAAG-3'. The upstream primer of m-BNP was 5'-AGTCGGAGGAAATGGC-3', and the downstream primer of m-BNP was 5'-CAACAACTTCAGTGCGTTA-3'. The upstream primer of m-MYH7 was 5'-GCTGGAAGATGAGTGCTCAGAG-3', and the downstream primer of m-MYH7 was 5'-TCCAAACCAGCCATCTCCTCTG-3'. The upstream primer of m-GAPDH was 5′-CATCACTGCCACCCAGAAGAC-3′, and the downstream primer of m-GAPDH was 5′-ATGCCAGTGAGCTTCCCGTTCAG-3′.

[0109] (5) Immunofluorescence staining was used to observe the area of ​​myocardial cells.

[0110] An appropriate amount of mouse primary cardiomyocytes were inoculated in a 24-well plate covered with a coverslip. After the cells adhered to the wall, they were infected with viruses and treated with drugs. After 48 hours, the cells were harvested for fluorescent staining. 500ul of 4% paraformaldehyde was added to each well, fixed at room temperature for 20 minutes, and washed 3 times with PBS. Then, 0.4% Tritonx-100 in PBS buffer was used for penetration at room temperature for 20 minutes, and 5% goat serum was blocked on a shaker at room temperature for 1 hour. Primary antibody (cTnT, 1:200) was added and incubated overnight at 4°C. The next day, after washing 3 times with PBS, fluorescent secondary antibody (cy3, 1:200) was added and incubated at room temperature in the dark for 1 hour. Then, PBS was washed 3 times, and DAPI (1:200) was added to the cells and incubated at room temperature for 15 minutes. After that, the field of view was randomly selected under a fluorescence microscope, photographed and saved, and the surface area of ​​cardiomyocytes was outlined using ImageJ software. At the same time, the relative area of ​​cardiomyocytes was read using arbitrary units, which was used as the basis for evaluating the degree of cardiomyocyte hypertrophy.

[0111] (6) CCK8 experiment

[0112] An appropriate amount of cardiac fibroblasts were inoculated in 96-well plates and infected with circSMAD3 overexpression or shRNA adenovirus for 24 hours, followed by stimulation with TGFβ1 for 24 hours. The CCK8 kit was used to detect cell proliferation for 72 hours. The wavelength was set to 450 nm in the spectrophotometer, the OD value of each well was detected, and the cell proliferation rate was calculated.

[0113] (7) EDU experiment

[0114] An appropriate amount of cardiac fibroblasts were seeded in 48-well plates and infected with circSMAD3 overexpression or shRNA adenovirus for 24 hours and then stimulated with TGFβ1 for 24 hours. After the intervention, the cells were incubated with 1:1000 diluted EDU solution at 37°C for 2 hours, fixed with 4% paraformaldehyde, and incubated with the mother buffer prepared according to the operating method provided by the EDU kit for 30 minutes. After incubation with DAPI for 15 minutes, the cells were washed three times with PBS. Fluorescence microscopy was used to take pictures, and the number of proliferating cells and total cells was counted by ImageJ software, and the ratio was calculated.

[0115] (8) Scratch test

[0116] An appropriate amount of cardiac fibroblasts were seeded in 6-well plates and infected with circSMAD3 overexpression or shRNA adenovirus for 24 hours and then stimulated with TGFβ1 for 24 hours. After 24 hours, the supernatant was discarded and the cells were washed with PBS buffer. Floating cells were scratched with a 200ul tip and washed with PBS buffer. Cells were continued to be cultured at 37°C with DMEM containing 10% FBS. Photos were taken under a microscope and the healing area was counted using ImageJ.

[0117] (9) HE staining

[0118] Take out the cut paraffin slices and place them in a 60℃ oven for 1h. 1) Dewaxing: pure xylene I, 5min, pure xylene II, 5min; 2) Hydration: pure ethanol I, 10min; pure ethanol II, 10min; 95% ethanol I, 5min; 85% ethanol, 5min; 75% ethanol, 5min; 50% ethanol, 5min; wash once with deionized water, 5min; 3) Staining: Hematoxylin staining: drop hematoxylin on the tissue and cover it for 2-3min; rinse with tap water, 3-4 times; then cover it with 1% hydrochloric acid ethanol solution for 2-3s; wash with tap water for 15min; drop eosin stain on the tissue and cover it for 30s; shake it in a basin of water, then reverse from 50% ethanol back to pure xylene II; finally seal the slide with neutral resin.

[0119] (10) Masson staining

[0120] The cut paraffin sections are dewaxed and hydrated with HE staining. Then perform the following operations: Stain with R1 nuclear stain solution for about 60 seconds, pour it out, and rinse with rinse solution for about 30 seconds. Stain with R2 slurry solution for about 30 seconds to 60 seconds, pour it out, and rinse with rinse solution for about 30 seconds. Separate with R3 yellow color separation solution for about 6 minutes to 8 minutes and discard the color separation solution. Stain directly with R4 blue counterstain solution for about 5 minutes, pour it out, and rinse with anhydrous ethanol. After drying, directly seal the slide with non-toxic and environmentally friendly fixing agent and examine under a microscope. Staining results: collagen fibers are blue; cytoplasm, cellulose, etc. are red; cell nuclei are blue-purple.

[0121] (11) WGA staining

[0122] The cut paraffin sections were dewaxed and hydrated as before HE staining. The subsequent operations were as follows: wash the slides twice with PBS; incubate with WGA-FITC antibody prepared with PBS for 1 hour; wash with PBS three times after incubation; seal with anti-fading sealant; and take photos with a fluorescence microscope.

[0123] (12) Statistical analysis

[0124] All experimental data were analyzed using Graphpad Prism 8.0 software. All data were expressed as mean ± SD or mean ± standard error (Mean ± SEM), and the significance of the differences was tested by one-way analysis of variance. The significant difference between the two groups of data was compared using the Bonferroni method, and the two-tailed probability of P < 0.05 was used as the standard for significant difference.

[0125] Example 2

[0126] This example provides an analysis of experimental results using circSMAD3 (nucleotide sequence as shown in SEQ ID NO. 1) as a marker for diagnosing pathological myocardial remodeling.

[0127] (1) Establishing an in vivo and in vitro experimental model of myocardial remodeling to detect the decrease in circSMAD3 expression during myocardial remodeling

[0128] This experiment adopted the steps in Example 1 and used transverse aortic constriction (TAC) to induce a mouse myocardial remodeling experimental model. After 8 weeks, ultrasound detection of aortic arch blood flow velocity and cardiac function confirmed that the mouse myocardial remodeling model was successfully established. The results showed that the cardiac function of mice in the TAC group was significantly decreased ( Figure 1 A). RNA was routinely extracted from mouse heart tissue, and qRT-PCR results showed that circSMAD3 expression was significantly reduced ( Figure 1 B).

[0129] This experiment used the steps in Example 1 to isolate cardiomyocytes and fibroblasts from mouse heart tissue 8 weeks after TAC surgery using a perfusion system. RNA was routinely extracted from the isolated cardiomyocytes and fibroblasts, and qRT-PCR results showed that the expression of circSMAD3 in cardiomyocytes and fibroblasts of mice 8 weeks after TAC surgery was significantly reduced ( Figure 1 C).

[0130] This experiment adopted the steps in Example 1 and used myocardial infarction (MI) to induce a mouse myocardial remodeling experimental model. Four weeks later, the cardiac function of the mice was tested by ultrasound to verify whether the myocardial remodeling model was successfully established. The results showed that the cardiac function of the mice in the MI group was significantly decreased ( Figure 1 D). RNA was routinely extracted from mouse heart tissue, and qRT-PCR results showed that the expression of circSMAD3 in MI mice was significantly reduced ( Figure 1 E).

[0131] Primary cardiac fibroblasts of neonatal mice were isolated and cultured in vitro using the steps in Example 1. Cardiomyocyte hypertrophy models were constructed by treating with angiotensin II (AngII) at concentrations of 0.01uM, 0.1uM, 1uM and 10uM for 24 hours. Total RNA of cardiomyocytes was extracted, and the expression of circSMAD3 was significantly reduced by real-time fluorescence quantitative PCR ( Figure 1 F). Cardiac fibroblasts were treated with TGFβ1 at concentrations of 1ng / ml, 2ng / ml, 5ng / ml, 10ng / ml and 20ng / ml for 24 hours to construct a cardiomyocyte remodeling model. Total RNA from cardiomyocytes was extracted and detected by real-time fluorescence quantitative PCR. It was found that the expression of circSMAD3 in the TGFβ1 group was also significantly reduced ( Figure 1 G).

[0132] Primary cardiomyocytes and cardiac fibroblasts of neonatal mice were isolated and cultured in vitro using the steps in Example 1. The expression abundance of circSMAD3 in cardiomyocytes and cardiac fibroblasts was not significantly different using qRT-PCR technology ( Figure 1 HI), indicating that circSMAD3 may play a key role in the regulation of both cardiac hypertrophy and myocardial fibrosis.

[0133] (2) circSMAD3 regulates angiotensin II-induced cardiac hypertrophy

[0134] Total RNA was extracted 48 hours after the cardiomyocytes were infected with circSMAD3 overexpression adenovirus. The efficiency of circSMAD3 overexpression and its effect on linear SMAD3 were detected by qRT-PCR. The circSMAD3 overexpression adenovirus was infected in the AngII-induced primary cardiomyocyte hypertrophy model of neonatal mice. The results showed that circSMAD3 overexpression significantly reduced the RNA levels of hypertrophy markers ANP, BNP and MYH7 ( Figure 2 A), cTNT immunofluorescence staining showed that overexpression of CircSMAD3 significantly inhibited the enlargement of cardiomyocyte area induced by AngII ( Figure 2 CD).

[0135] The primary cardiomyocytes of neonatal mice were infected with shRNA knockdown adenovirus based on short hairpin structure to silence circSMAD3 and evaluate the knockdown efficiency of circSMAD3 shRNA and the effect on SMAD3 linear RNA. Total RNA was extracted 48 hours after the cardiomyocytes were infected with circSMAD3 knockdown adenovirus to detect the content of circSMAD3. The results showed that the expression of circSMAD3 was significantly inhibited, and there was no significant effect on SMAD3 linear RNA. In addition, the RNA levels of hypertrophy markers ANP, BNP and MYH7 were significantly increased compared with the control group cells ( Figure 2 B). cTNT immunofluorescence staining showed that knockdown of circSMAD3 increased the area of ​​cardiomyocytes ( Figure 3 EF).

[0136] (3) circSMAD3 regulates TGFβ1-induced cardiac fibroblast activation

[0137] After 48 hours of infection of cardiac fibroblasts with circSMAD3 overexpression adenovirus, total RNA was extracted. The efficiency of circSMAD3 overexpression and its effect on linear SMAD3 were detected by qRT-PCR. CircSMAD3 overexpression adenovirus was infected in the TGFβ1-induced myocardial remodeling model of neonatal mouse cardiac fibroblasts. After 24 hours, qRT-PCR was used to detect the RNA levels of myocardial fibrosis markers, and the proliferation and migration ability of cardiac fibroblasts was detected. The results showed that circSMAD3 significantly inhibited the RNA levels of fibrosis markers induced by TGFβ1 ( Figure 3 A). CCK8, EDU and scratch assays showed that circSMAD3 overexpression significantly inhibited the proliferation and migration of fibroblasts induced by TGFβ1 ( Figure 3 CL).

[0138] The primary cardiac fibroblasts of neonatal mice were infected with shRNA knockdown adenovirus based on short hairpin structure to silence circSMAD3 and evaluate the knockdown efficiency of circSMAD3shRNA and the effect on SMAD3 linear RNA. Total RNA was extracted 48 hours after the cardiac fibroblasts were infected with circSMAD3 knockdown adenovirus to detect the content of circSMAD3. The results showed that the expression of circSMAD3 was significantly inhibited, and there was no significant effect on SMAD3 linear RNA. The RNA levels of fibrosis markers CollagenI, Collagen III and ACTA2 were also significantly increased compared with the control group cells ( Figure 3 B). CCK8, EDU and scratch assays all showed that circSMAD3 knockdown significantly increased the proliferation and migration of cardiac fibroblasts ( Figure 3 DL).

[0139] (4) circSMAD3 effectively alleviates TAC-induced pathological myocardial remodeling in mice

[0140] To further explore the preventive and therapeutic effects of circSMAD3 on pathological myocardial remodeling, adeno-associated virus type 9 (AAV9) virus overexpressing circSMAD3 specifically in mice was injected through the tail vein 3 weeks before TAC surgery, and the empty vector was used as a control. The results showed that the expression level of circSMAD3 group was significantly higher than that of the control group ( Figure 4 A). Ultrasound detection of aortic arch blood flow velocity and cardiac function showed that 8 weeks after TAC surgery, circSMAD3 overexpression significantly rescued the decrease in left ventricular ejection fraction and shortening fraction caused by TAC, and improved the abnormal cardiac function of mice caused by TAC surgery ( Figure 4BD). Moreover, circSMAD3 overexpression significantly reversed the increase in heart weight (HW) / tibia length (TL) ratio induced by TAC ( Figure 4 EF). The heart was histologically analyzed by H&E, WGA and picrosirius red staining. The results showed that circSMAD3 overexpression significantly inhibited the enlargement of the heart and cardiomyocytes and reduced the level of myocardial fibrosis in the TAC group mice (Figure 6E-H). Similarly, the mRNA levels of ANP, BNP, MYH7, Collagen I, Collagen III and ACTA2 in the circSMAD3 overexpression group mice also decreased (Figure 6I).

[0141] (5) circSMAD3 significantly improves MI-induced pathological myocardial remodeling in mice

[0142] In order to further explore the preventive and therapeutic effects of circSMAD3 on pathological myocardial remodeling, the function of circSMAD3 was further clarified in a mouse model of myocardial infarction. Similarly, adeno-associated virus type 9 (AAV9) virus overexpressing circSMAD3 specifically in the heart was injected into the mouse tail vein 3 weeks before MI surgery, and the empty vector was used as a control. Qrt-PCR results showed that the expression level of circSMAD3 group was significantly higher than that of the control group ( Figure 5 A), and the mRNA levels of ANP, BNP, MYH7, Collagen I, Collagen III, and ACTA2 in the circSMAD3 overexpression group were also decreased (( Figure 5 BG). The cardiac function of mice was detected by ultrasound, and the results showed that 4 weeks after MI surgery, circSMAD3 overexpression significantly rescued the decrease in left ventricular ejection fraction and shortening fraction caused by MI, and improved the abnormal cardiac function of mice caused by MI surgery ( Figure 5 IJ). Moreover, circSMAD3 overexpression significantly reversed the increase in heart weight (HW) / tibia length (TL) ratio induced by MI surgery ( Figure 5 H). Masson staining was used to perform histological morphological analysis of the heart, and the results showed that circSMAD3 overexpression significantly inhibited the level of myocardial fibrosis in the MI group ( Figure 5 KL).

[0143] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Application of circSMAD3 as a marker for the diagnosis of myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

2. The use of circSMAD3 as a marker for the diagnosis of myocardial remodeling and heart failure according to claim 1, characterized in that: The expression of circSMAD3 was reduced in cardiac tissue, cardiomyocytes and cardiac fibroblasts in pathological myocardial remodeling; inhibition of circSMAD3 expression in vitro could induce pathological myocardial remodeling.

3. The use of circSMAD3 as a marker for the diagnosis of myocardial remodeling and heart failure according to claim 1, characterized in that: Overexpression of circSMAD3 in vitro can significantly inhibit pathological myocardial remodeling; heart-specific overexpression of circSMAD3 in vivo can significantly inhibit pathological myocardial remodeling.

4. A diagnostic kit for myocardial remodeling and heart failure, characterized in that: It includes the circSMAD3 described in claim 1, and the nucleotide sequence of the circSMAD3 is shown as SEQ ID NO.

1.

5. Application of circSMAD3 in screening diagnostic drugs for myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

6. Application of circSMAD3 in a diagnostic kit for screening myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

7. Use of circSMAD3 in the preparation of a drug for preventing or treating myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

8. Application of circSMAD3 in preparing a kit for myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

9. Use of a circSMAD3 activator in the preparation of a drug for preventing or treating myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.

1.

10. Use of a circSMAD3 activator in preparing a kit for myocardial remodeling and heart failure, characterized in that: The nucleotide sequence of circSMAD3 is shown in SEQ ID NO.1.

Citation Information

Cited By

  • Circular RNA (Ribonucleic Acid) medicine for treating heart failure and application thereof

    CN119770510A

  • Circular RNA drugs for treating heart failure and their applications

    CN119770510B